Zojirushi Mahobin <7965>: 1,511 yen (-48 yen)

Significantly down. The interim financial results were announced the day before, and operating profit decreased by 2.4% compared to the same period last year to 4.37 billion yen. The first quarter was the same, and the full-year forecast remains at 5.2 billion yen, a 4.0% increase over the previous year. An increase in selling and administrative expenses and negative effects of foreign exchange are likely affecting the result. The company announced a share buyback program outside the market and has bought 2,098,600 shares today, with 2.5 million shares being the upper limit on shares outstanding to implement the program.

Keeper Technology <6036>: 3,775 yen (-295 yen)

Significantly down. At Tokai Tokyo Securities, investment rating was downgraded from 'outperform' to 'neutral,' and the target stock price was lowered from 6,500 yen to 4,150 yen, reflecting a slowdown in the sales growth rate of existing Keeper LABO stores and risks of decreasing domestic new car sales units. The operating profit for the fiscal year 2025 is estimated to be 6.93 billion yen due to a decrease from the previous expectation of 7.56 billion yen, which was 13.4% higher than the previous year. Recovery in the semiconductor market conditions and bullish announcements of product sales for new car dealerships are required for the share price to recover.

Horiba <6856>: 13,325 yen (+540 yen)

Significantly up. Jefferies Securities upgraded its investment rating from 'hold' to 'buy' and increased the target stock price from 15,000 yen to 16,000 yen, citing a revaluation of the low price-to-earnings ratio and a recovery of the semiconductor market and reconsideration of foreign exchange rates. The operating profit for the fiscal year ending in December 2024 is estimated to be 52.5 billion yen, an 11.0% increase from the previous expectation of 50.8 billion yen.

Nextage <3186>: 2,289 yen (-125 yen)

Significantly down. Interim financial results were announced the previous day, and the operating profit decreased by 2.6% from the same period last year to 7.8 billion yen. The results for the period from March to May decreased by 10.5% from the increase of 25.2% in the first quarter. The full-year forecast remains at 20.0 billion yen, a 24.3% increase over the previous year but the progress is lagging behind compared to the previous term. Some also point out the increasing staff turnover, which is leading to a deterioration in gross profit related to incidental revenue.

Star Mica Holdings <2975>: 682 yen (+43 yen)

Significantly up. The interim financial results were announced the day before, and the operating profit increased by 2.3% from the same period last year to 2.87 billion yen, exceeding the previous estimate of 2.52 billion yen. This result was achieved by converting a 9.0% decrease in the first quarter into an increase. Rental revenue and increased sales units have boosted the gross profit of the renovation condominium business, and the investment and advisory businesses are also making steady progress. The full-year forecast remains at 50.3 billion yen, a 3.8% increase over the previous year.

Linkers <5131>: 222 yen (+3 yen)

After rising in the morning, the price turned into congestion. After the end of the trading day on 1st, it was announced that Linkers for Bank, a business matching system for financial institutions, will be introduced to Fukui Bank. The company has already introduced the system to 42 institutions since its launch and is expanding its network across the country. The share price is expected to rebound if the company can recover the growth of the existing stores and make bullish announcements of product sales to new car dealerships.

Tasuki Holdings <166A>: 626 yen (+13 yen)

Up. ZISEDAl, a subsidiary of the company, has obtained a patent for the architecture plan generation AI service TASUKI TECH TOUCH & PLAN and has started providing it to real estate developers. TOUCH & PLAN can calculate the volume check (volume rate survey, etc.) in about 5 minutes per item, and can significantly reduce the time and cost compared to conventional volume check operations (1 account monthly fee of 100,000 yen), realizing the homogenization of skills of purchasing officials and faster business consideration.

Ribomic <4591>: 118 yen (+25 yen)

The stock temporarily hit its maximum limit. The enrollment of patients for the Phase II clinical trial of umedaptanib pegol (anti-FGF2 aptamer), a treatment for cartilage agenesis in pediatric patients (aged 5 to 14), has been completed, and high-dose subcutaneous administration trials (cohort 2) have begun for patients who have completed the observation trial, resulting in a favorable response. There are currently no safety concerns raised in the ongoing Phase II clinical trial and Phase II long-term administration trial.